Immune reconstitution is not a prognostic factor in progressive multifocal leukoencephalopathy

Journal of Neuroimmunology

Volumn 238, Issue 1-2, 2011, Pages 81-86

  Harrison, Daniel M ^a   Newsome, Scott D ^a   Skolasky, Richard L ^a   McArthur, Justin C ^a,b   Nath, Avindra ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

HIV; Immune reconstitution inflammatory syndrome; Immunosuppression; Leukoencephalopathy; Progressive multifocal

Indexed keywords

GADOLINIUM; PROTEIN;

ADULT; ARTICLE; BLOOD CELL COUNT; CD4 LYMPHOCYTE COUNT; CEREBROSPINAL FLUID; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE SYSTEM; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

ANTIGENS, CD4; BLOOD CELL COUNT; CD4 LYMPHOCYTE COUNT; CELL SURVIVAL; GADOLINIUM; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MAGNETIC RESONANCE IMAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 81155160126     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2011.07.003     Document Type: Article

References (30)

1. Antinori A., Ammassari A., et al. Epidemiology and prognosis of AIDS-associated progressive multifocal leukoencephalopathy in the HAART era. J. Neurovirol. 2001, 7(4):323-328.
2. Berger J.R., Levy R.M., et al. Predictive factors for prolonged survival in acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy. Ann. Neurol. 1998, 44(3):341-349.
3. Berger J.R., Pall L., et al. Progressive multifocal leukoencephalopathy in patients with HIV infection. J. Neurovirol. 1998, 4(1):59-68.
4. Brooks B.R., Walker D.L. Progressive multifocal leukoencephalopathy. Neurol. Clin. 1984, 2(2):299-313.
5. Carson K.R., Evens A.M., et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009, 113(20):4834-4840.
6. Cinque P., Pierotti C., et al. The good and evil of HAART in HIV-related progressive multifocal leukoencephalopathy. J. Neurovirol. 2001, 7(4):358-363.
7. Cinque P., Bossolasco S., et al. The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: study of 43 cases with review of the literature. J. Neurovirol. 2003, 9(Suppl 1):73-80.
8. Clifford D.B., Yiannoutsos C., et al. HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology 1999, 52(3):623-625.
9. Clifford D.B., De Luca A., et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010, 9(4):438-446.
10. Dhasmana D.J., Dheda K., et al. Immune reconstitution inflammatory syndrome in HIV-infected patients receiving antiretroviral therapy: pathogenesis, clinical manifestations and management. Drugs 2008, 68(2):191-208.
11. Engsig F.N., Hansen A.B., et al. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J. Infect. Dis. 2009, 199(1):77-83.
12. Falco V., Olmo M., et al. Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observational multicenter study. J. Acquir. Immune. Defic. Syndr. 2008, 49(1):26-31.
13. Holman R.C., Janssen R.S., et al. Epidemiology of progressive multifocal leukoencephalopathy in the United States: analysis of national mortality and AIDS surveillance data. Neurology 1991, 41(11):1733-1736.
14. Holman R.C., Torok T.J., et al. Progressive multifocal leukoencephalopathy in the United States, 1979-1994: increased mortality associated with HIV infection. Neuroepidemiology 1998, 17(6):303-309.
15. Huang D., Cossoy M., et al. Inflammatory progressive multifocal leukoencephalopathy in human immunodeficiency virus-negative patients. Ann. Neurol. 2007, 62(1):34-39.
16. Johnson T., Nath A. Neurological complications of immune reconstitution in HIV-infected populations. Ann. N. Y. Acad. Sci. 2010, 1184:106-120.
17. Linda H., von Heijne A., et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J. Med. 2009, 361(11):1081-1087.
18. Manabe Y.C., Campbell J.D., et al. Immune reconstitution inflammatory syndrome: risk factors and treatment implications. J. Acquir. Immune Defic. Syndr. 2007, 46(4):456-462.
19. Martinez J.V., Mazziotti J.V., et al. Immune reconstitution inflammatory syndrome associated with PML in AIDS: a treatable disorder. Neurology 2006, 67(9):1692-1694.
20. McCombe J.A., Auer R.N., et al. Neurologic immune reconstitution inflammatory syndrome in HIV/AIDS: outcome and epidemiology. Neurology 2009, 72(9):835-841.
21. Padgett B.L., Walker D.L., et al. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1971, 1(7712):1257-1260.
22. Post M.J., Yiannoutsos C., et al. Progressive multifocal leukoencephalopathy in AIDS: are there any MR findings useful to patient management and predictive of patient survival? AIDS Clinical Trials Group, 243 Team. AJNR Am. J. Neuroradiol. 1999, 20(10):1896-1906.
23. Rushing E.J., Liappis A., et al. Immune reconstitution inflammatory syndrome of the brain: case illustrations of a challenging entity. J. Neuropathol. Exp. Neurol. 2008, 67(8):819-827.
24. Shelburne S.A., Visnegarwala F., et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005, 19(4):399-406.
25. Shelburne S.A., Montes M., et al. Immune reconstitution inflammatory syndrome: more answers, more questions. J. Antimicrob. Chemother. 2006, 57(2):167-170.
26. Tan K., Roda R., et al. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology 2009, 72(17):1458-1464.
27. Thachil J. A clue to the pathophysiology of posterior reversible encephalopathy syndrome. Arch. Neurol. 2010, 67(12):1536-1537. 1536; author reply.
28. Thurnher M.M., Post M.J., et al. Initial and follow-up MR imaging findings in AIDS-related progressive multifocal leukoencephalopathy treated with highly active antiretroviral therapy. AJNR Am. J. Neuroradiol. 2001, 22(5):977-984.
29. Vendrely A., Bienvenu B., et al. Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDS-related progressive multifocal leukoencephalopathy. Acta Neuropathol. 2005, 109(4):449-455.
30. Wong D., Dorovini-Zis K., et al. Cytokines, nitric oxide, and cGMP modulate the permeability of an in vitro model of the human blood-brain barrier. Exp. Neurol. 2004, 190(2):446-455.